Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-904X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety ; volume:38 ; number:4 ; day:17 ; month:3 ; year:2021 ; pages:593-605 ; date:4.2021
Pharmaceutical research ; 38, Heft 4 (17.3.2021), 593-605, 4.2021
- Creator
-
Minichmayr, Iris K.
Karlsson, Mats O.
Jönsson, Siv
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11095-021-03024-w
- URN
-
urn:nbn:de:101:1-2021060621471964872397
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Minichmayr, Iris K.
- Karlsson, Mats O.
- Jönsson, Siv
- SpringerLink (Online service)
Other Objects (12)
User considerations in assessing pharmacogenomic tests and their clinical support tools
Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy
Safety considerations for biotechnology 1992
The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma
Comprehensive pharmacogenomic characterization of gastric cancer
Food safety and quality : trade considerations
Pediatric interventional radiography equipment: safety considerations
Reply to Sun: Dynamic and accessible pharmacogenomic results: a response to pharmacogenomic testing for antidepressant treatment selection
A Landscape of Pharmacogenomic Interactions in Cancer
GDSCTools for Mining Pharmacogenomic Interactions in Cancer
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model
User considerations in assessing pharmacogenomic tests and their clinical support tools
Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy
Safety considerations for biotechnology 1992
The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma
Comprehensive pharmacogenomic characterization of gastric cancer
Food safety and quality : trade considerations
Pediatric interventional radiography equipment: safety considerations
Reply to Sun: Dynamic and accessible pharmacogenomic results: a response to pharmacogenomic testing for antidepressant treatment selection
A Landscape of Pharmacogenomic Interactions in Cancer
GDSCTools for Mining Pharmacogenomic Interactions in Cancer
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model
User considerations in assessing pharmacogenomic tests and their clinical support tools
Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy
Safety considerations for biotechnology 1992
The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma
Comprehensive pharmacogenomic characterization of gastric cancer
Food safety and quality : trade considerations
Pediatric interventional radiography equipment: safety considerations
Reply to Sun: Dynamic and accessible pharmacogenomic results: a response to pharmacogenomic testing for antidepressant treatment selection
A Landscape of Pharmacogenomic Interactions in Cancer
GDSCTools for Mining Pharmacogenomic Interactions in Cancer
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity